Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | LPO | P22079 | 4/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25045667 | 0.81 | BRD4 (0.36) | PDE4AADORA2AADORA2BPDE4BPDE4C | |
| SCHEMBL13483449 | 0.79 | TLR8 (0.42) | ADORA2AADORA2BALDH1A1LMNAMAPT | |
| SCHEMBL4623309 | 0.78 | MAPT (0.39) | GSK3AGSK3BLPOPDE4AADORA2A | |
| SCHEMBL12128675 | 0.78 | ADORA2B (0.31) | ADORA2AADORA2B | |
| SCHEMBL10123555 | 0.76 | ALDH1A1 (0.40) | ADORA2BALDH1A1LMNAMAPT | |
| SCHEMBL23945484 | 0.74 | LPO (0.42) | LPOALDH1A1 | |
| SCHEMBL14600369 | 0.74 | KMT2A (0.45) | ADORA2BALDH1A1MAPT | |
| SCHEMBL13482107 | 0.70 | PTGS1 (0.42) | CCNT1CDK9LMNA | |
| SCHEMBL6736338 | 0.70 | LPO (0.32) | LPOADORA2B | |
| SCHEMBL14257134 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230322771-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-8318742-B2 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-11-27 | — | — | US | disclosed |
| US-20120028987-A1 | Bicyclic Benzamides of 3-Or-4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-02 | — | — | US | disclosed |
| US-8063070-B2 | Bicyclic benzamides of 3-or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-11-22 | — | — | US | disclosed |
| US-7790750-B2 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-20100210657-A1 | Bicyclic Benzamides of 3-or 4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-19 | — | — | US | disclosed |
| US-RE40793-E1 | Bicyclic benzamides of 3-or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GSK3A 710/4885GSK3B 663/4885CCNT1 4407/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GSK3A 710/4885GSK3B 663/4885CCNT1 4407/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GSK3A 710/4885GSK3B 663/4885CCNT1 4407/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | GSK3A 320/4885GSK3B 328/4885CCNT1 1822/4885 |
| US-20120028987-A1 | Bicyclic Benzamides of 3-Or-4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | HRH2, SLC10A2, HRH4 | GSK3A 3851/4885GSK3B 3784/4885CCNT1 2385/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GSK3A 710/4885GSK3B 663/4885CCNT1 4407/4885 |
| US-20230322771-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | GSK3A 1945/4885GSK3B 1772/4885CCNT1 3629/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GSK3A 710/4885GSK3B 663/4885CCNT1 4407/4885 |
| US-20100210657-A1 | Bicyclic Benzamides of 3-or 4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | HRH2, HRH4, PGC | GSK3A 3929/4885GSK3B 3869/4885CCNT1 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.